NCT04120246View on ClinicalTrials.gov

Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer

PHASE1SuspendedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

April 8, 2020

Primary Completion Date

February 1, 2028

Study Completion Date

February 1, 2030

Conditions
Anatomic Stage IV Breast Cancer AJCC v8HER2 Positive Breast CarcinomaMetastatic Breast CarcinomaRefractory Breast Carcinoma
Interventions
DRUG

Alpha-tocopheryloxyacetic Acid

Given PO

BIOLOGICAL

Trastuzumab

Given IV

Trial Locations (2)

97213

Providence Cancer Institute - Franz Clinic, Portland

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Lead Sponsor

Veana Therapeutics
All Listed Sponsors
collaborator

University of Washington

OTHER

lead

Veana Therapeutics

INDUSTRY

NCT04120246 - Alpha-TEA and Trastuzumab for the Treatment of Refractory HER2+ Metastatic Breast Cancer | Biotech Hunter | Biotech Hunter